欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01477 欧康维视生物-B

未开盘 06-24 16:08:03

4.640

-0.030

-0.64%

最高4.790	最低4.620	成交量95.55万
今开4.740	昨收4.670	日振幅3.64%
总市值37.82亿	流通市值37.82亿	总股本8.15亿
成交额447.48万	换手率0.12%	流通股本8.15亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01477","market":"HK","secType":"STK","nameCN":"欧康维视生物-B","latestPrice":4.64,"timestamp":1782288483004,"preClose":4.67,"halted":0,"volume":955500,"delay":0,"changeRate":-0.006423982869379069,"floatShares":815000000,"shares":815000000,"eps":-0.2,"marketStatus":"未开盘","change":-0.03,"latestTime":"06-24 16:08:03","open":4.74,"high":4.79,"low":4.62,"amount":4474815,"amplitude":0.036403,"askPrice":4.64,"askSize":10000,"bidPrice":4.62,"bidSize":2500,"shortable":3,"etf":0,"ttmEps":-0.223378,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782351000000},"marketStatusCode":0,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":4.67,"openAndCloseTimeList":[[1782264600000,1782273600000],[1782277200000,1782288000000]],"volumeRatio":0.976905,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01477","defaultTab":"news","newsList":[{"id":"2645896917","title":"歌礼制药-B(01672)6月24日斥资201.81万港元回购20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2645896917","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645896917?lang=zh_cn&edition=full","pubTime":"2026-06-24 17:12","pubTimestamp":1782292374,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)发布公告，于2026年6月24日斥资201.81万港元回购20万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1458093.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","BK1515","01672","BK1191","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645895587","title":"泽璟制药涨11.00%，东吴证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2645895587","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645895587?lang=zh_cn&edition=full","pubTime":"2026-06-24 16:38","pubTimestamp":1782290309,"startTime":"0","endTime":"0","summary":"今日泽璟制药（688266）涨11.00%，收盘报99.58元。2026年3月30日，东吴证券研究员朱国广,苏丰发布了对泽璟制药的研报《2025年年报点评：商业化持续兑现，看好公司核心管线BIC潜力》，该研报对泽璟制药给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为61.37%。此外，华源证券研究员刘闯，开源证券研究员余汝意,聂媛媛近期也对该股发布了研报，同样给出“买入”评级。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为西部证券的吴天昊。泽璟制药（688266）个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400030020.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601555","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645872788","title":"歌礼制药-B(01672)宣布其每月一次皮下注射GLP-1R/GIPR双靶点激动剂多肽ASC35治疗肥胖症的I期研究IND获美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2645872788","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645872788?lang=zh_cn&edition=full","pubTime":"2026-06-23 18:04","pubTimestamp":1782209049,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 公布，近期已获得美国食品药品监督管理局对其ASC35的I期研究的新药临床试验批准。ASC35是一款有望成为同类最佳、每月一次皮下注射的GLP-1受体/GIP受体 双靶点激动剂多肽，用于治疗肥胖症。体外实验显示，ASC35对GLP-1R和GIPR的激动活性比替尔泊肽强约4倍。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457577.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","GLP","01672","BK4590","IND","01477","BK4588","BK4160","BK1515","LABU","BK1574","BK4144","BK4585","BK1191","GIPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645222700","title":"再生元制药(REGN)重症肌无力创新药获美欧监管受理  有望成全球首款治疗该症的siRNA药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2645222700","media":"金吾财讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645222700?lang=zh_cn&edition=full","pubTime":"2026-06-22 20:32","pubTimestamp":1782131526,"startTime":"0","endTime":"0","summary":"该药用于治疗抗乙酰胆腺受体抗体阳性的成人全身型重症肌无力患者。作为一款针对补体系统C5靶点的小干扰RNA疗法，Cemdisiran若能获批，有望成为全球首款用于治疗gMG的siRNA药物。目前，Cemdisiran仍处于临床研究阶段，其安全性和疗效尚未获得任何国家监管机构的最终批准。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250107/OTA0YzE0M2JmNDRmODg4Nzg5OWVhODM3NzhmNzU4MTEwODUxNDg2MTkzOA==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/OTA0YzE0M2JmNDRmODg4Nzg5OWVhODM3NzhmNzU4MTEwODUxNDg2MTkzOA==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"301751","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823434740.USD","LU2023250504.SGD","BK1574","LU2106854487.HKD","LU2237438978.USD","LU2362540622.SGD","LU0053666078.USD","BK4588","LU0823434583.USD","06978","LU2468319806.SGD","BK1191","LU0889565916.HKD","BK4139","BK4585","BK1161","LU1974910355.USD","LU2362541513.USD","LU1917777945.USD","LU2362541273.HKD","LU0882574055.USD","LU2089984988.USD","LU0320765992.SGD","LU0114720955.EUR","LU0289739699.SGD","01477","LU0109394709.USD","159992","LU0058720904.USD","REGN","LU0823416689.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645002593","title":"歌礼制药-B(01672)6月22日斥资190.1万港元回购20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2645002593","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645002593?lang=zh_cn&edition=full","pubTime":"2026-06-22 18:05","pubTimestamp":1782122704,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)发布公告，于2026年6月22日，该公司斥资190.1万港元回购20万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456988.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1191","BK1515","BK1574","01672","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645042867","title":"董秘说|健友股份董秘黄锡伟：锚定全球化布局，三步走夯实制药全产业链成长","url":"https://stock-news.laohu8.com/highlight/detail?id=2645042867","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645042867?lang=zh_cn&edition=full","pubTime":"2026-06-22 15:41","pubTimestamp":1782114060,"startTime":"0","endTime":"0","summary":"　　炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　在资本市场高质量发展的新阶段，上市公司价值传递的枢纽——董事会秘书，始终是连接企业与万千投资者的坚实桥梁，是资本品牌的核心锻造者与市场信任的关键构建者。由新浪财经主办的第十二届金麒麟·金牌董秘评选火热进行中，评选期间推出《董秘说》专访活动，助力投资者深入了解上市公司资本价值和发展战略。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/roll/2026-06-22/doc-iniehmvv9317391.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0046","BK0186","BK1574","603707","BK1191","01477","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645744010","title":"新股消息 | 泽璟制药(688266.SH)港股IPO招股书失效","url":"https://stock-news.laohu8.com/highlight/detail?id=2645744010","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645744010?lang=zh_cn&edition=full","pubTime":"2026-06-22 10:53","pubTimestamp":1782096824,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，苏州泽璟生物制药股份有限公司(简称：泽璟制药，688266.SH)于2025年12月19日所递交的港股招股书满6个月，于2026年6月19日失效，递表时中金公司为其独家保荐人。招股书显示，泽璟制药为一家综合生物制药企业，专注于创新型小分子及生物制剂疗法的发现、研发及商业化，策略聚焦于肿瘤学、自身免疫性疾病、止血/血液病领域。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456752.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688266","BK4585","VXUS","BK0239","01477","IPOS","BK1574","BK4588","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645018382","title":"中新健康｜创新药企集体拥抱，AI制药竞赛按下加速键","url":"https://stock-news.laohu8.com/highlight/detail?id=2645018382","media":"中国新闻网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645018382?lang=zh_cn&edition=full","pubTime":"2026-06-21 22:22","pubTimestamp":1782051744,"startTime":"0","endTime":"0","summary":"中新网北京6月21日电(记者赵方园)进入2026年，AI制药已经从“要不要做”的选择题，变成一场“谁跑得更快”的新竞赛。近日，和铂医药与百图生科联合宣布，双方将共同创立面向全球市场的新型AI研发公司MegaStreamTechBio。这家新公司将整合百图生科2680亿参数的全模态生命科学大模型xTrimo，同时融合和铂医药在全球全人源抗体领域多年的海量高质量数据资产。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606213777099984.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606213777099984.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ARTY","06978","BK1161","CHAT","159992","AGIX","BK1191","01477","AIPO","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645094126","title":"药闻｜ 从项目合作到合资建企 AI制药探索复杂大分子研发新范式","url":"https://stock-news.laohu8.com/highlight/detail?id=2645094126","media":"新华财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645094126?lang=zh_cn&edition=full","pubTime":"2026-06-21 12:27","pubTimestamp":1782016036,"startTime":"0","endTime":"0","summary":"新华财经上海6月21日电（记者杜康）人工智能在药物研发中的应用已不鲜见，但AI公司与制药企业跨越传统技术服务或单一项目授权边界，联合注资成立独立研发公司的案例仍相对少见。近日，和铂医药（02142.HK）与百图生科联合宣布建立多层次、长周期全面战略合作伙伴关系，并围绕复杂大分子药物的AI研发，联合创立面向全球市场的新型AI管线研发公司MegaStreamTechBio。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606213776990078.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","01477","AIPO","AGIX","CHAT","BK1191","ARTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644206581","title":"每周股票复盘：汇宇制药（688553）HY07121皮下注射获临床受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2644206581","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644206581?lang=zh_cn&edition=full","pubTime":"2026-06-20 02:43","pubTimestamp":1781894590,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，汇宇制药报收于10.88元，较上周的16.36元下跌33.5%。本周，汇宇制药6月16日盘中最高价报16.42元。汇宇制药当前最新总市值68.1亿元，在化学制药板块市值排名71/150，在两市A股市值排名2616/5206。本周关注点公司公告汇总：注射用HY07121获药物临床试验受理通知书。此前已获批静脉给药途径临床试验，现新增皮下注射途径，旨在提升患者便利性并降低CRS等副作用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062000000843.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688553","BK1574","BK0239","BK1191","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644063790","title":"每周股票复盘：泽璟制药（688266）吉卡昔替尼获准治重度斑秃","url":"https://stock-news.laohu8.com/highlight/detail?id=2644063790","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644063790?lang=zh_cn&edition=full","pubTime":"2026-06-20 02:28","pubTimestamp":1781893693,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，泽璟制药报收于89.69元，较上周的92.88元下跌3.43%。本周关注点公司公告汇总：盐酸吉卡昔替尼片治疗成人重度斑秃适应症获批上市。公司公告汇总泽璟制药关于自愿披露盐酸吉卡昔替尼片治疗重度斑秃适应症上市申请获得批准的公告苏州泽璟生物制药股份有限公司收到国家药品监督管理局核准签发的《药品注册证书》，公司自主研发的盐酸吉卡昔替尼片用于治疗成人重度斑秃的上市申请获得批准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062000000717.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01477","BK1191","688266","BK0239","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644743347","title":"歌礼制药-B(01672)6月17日斥资197.09万港元回购20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2644743347","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644743347?lang=zh_cn&edition=full","pubTime":"2026-06-17 19:23","pubTimestamp":1781695410,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)发布公告，于2026年6月17日斥资197.09万港元回购20万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455698.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01672","01477","BK1515","BK1574","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644743606","title":"从卖药到管病，AI健康助手为制药商与患者“搭桥”","url":"https://stock-news.laohu8.com/highlight/detail?id=2644743606","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644743606?lang=zh_cn&edition=full","pubTime":"2026-06-17 19:19","pubTimestamp":1781695173,"startTime":"0","endTime":"0","summary":"在医疗健康领域，数字技术正重塑患者服务模式，AI工具也在加速成为制药商与患者之间的连接器。近日，在诺华的患者日活动上，蚂蚁健康数字医药行业负责人步晓龙表示，越来越多的患者正在使用AI工具获取健康建议，包括解读体检报告，健康管理的场景已经不仅仅局限在医院，也在深度融入患者的生活日常。患者对AI工具的使用更加频繁，加强了互联网健康平台的患者粘性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606173774747288.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606173774747288.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["AGIX","AIPO","BK1191","CHAT","ARTY","BK1574","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644136716","title":"中密控股：公司产品的新应用市场目前主要集中于储能、新能源、海工、制药等应用领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2644136716","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644136716?lang=zh_cn&edition=full","pubTime":"2026-06-17 15:27","pubTimestamp":1781681231,"startTime":"0","endTime":"0","summary":"证券之星消息，中密控股06月17日在投资者关系平台上答复投资者关心的问题。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700020600.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300470","000941.SH","160640","399941","BK0259","BK1191","159875","01477","IE0005HP3H50.USD","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643593237","title":"歌礼制药-B(01672)6月16日斥资186.26万港元回购20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2643593237","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643593237?lang=zh_cn&edition=full","pubTime":"2026-06-16 18:47","pubTimestamp":1781606872,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)发布公告，该公司于2026年6月16日斥资186.26万港元回购20万股股份，每股回购价格为9.14-9.45港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455074.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01672","BK1515","BK1574","01477","BK1191","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643274825","title":"歌礼制药-B(01672)6月15日斥资191.83万港元回购20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2643274825","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643274825?lang=zh_cn&edition=full","pubTime":"2026-06-15 17:40","pubTimestamp":1781516414,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)发布公告，于2026年6月15日，该公司斥资191.83万港元回购20万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454447.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01477","01672","BK1515","BK1574","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643278757","title":"开能健康：工业水处理涵盖电力锅炉补给水、电子工业用水、化工、制药、海水淡化等领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2643278757","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643278757?lang=zh_cn&edition=full","pubTime":"2026-06-15 15:15","pubTimestamp":1781507718,"startTime":"0","endTime":"0","summary":"证券之星消息，开能健康06月15日在投资者关系平台上答复投资者关心的问题。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061500012665.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01477","BK0020","159146","BK0135","BK0224","BK1191","300272","BK0150","BK0046","BK1574","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642228549","title":"歌礼制药-B(01672)6月11日斥资196.69万港元回购20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642228549","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642228549?lang=zh_cn&edition=full","pubTime":"2026-06-11 18:30","pubTimestamp":1781173810,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)发布公告，该公司于2026年6月11日斥资196.69万港元回购20万股股份，每股回购价格为9.63-10.11港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453231.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","01477","BK1574","01672","BK1191","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642400992","title":"百奥泰：公司于2026年5月11日参加科创板企业成果转化与民生赋能之2025年度制药行业集体业绩说明会暨召开2026年第一季度业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2642400992","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642400992?lang=zh_cn&edition=full","pubTime":"2026-06-11 16:54","pubTimestamp":1781168056,"startTime":"0","endTime":"0","summary":"证券之星消息，百奥泰06月11日在投资者关系平台上答复投资者关心的问题。公司于2026年5月11日在上海证券交易所上证路演中心参加了十五五·科创惠民——科创板企业成果转化与民生赋能之2025年度制药行业集体业绩说明会暨召开2026年第一季度业绩说明会，说明会中对公司2025年年度及2026年第一季度的经营情况做了详细解读，公司也对投资者关注的问题做了回复并披露了投资者关系活动记录表。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061100026318.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK0239","159982","01477","BK1191","688177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642440659","title":"歌礼制药-B(01672)6月10日斥资199.96万港元回购20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642440659","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642440659?lang=zh_cn&edition=full","pubTime":"2026-06-10 18:28","pubTimestamp":1781087318,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)发布公告，该公司于2026年6月10日斥资199.96万港元回购20万股股份，每股回购价格为9.75-10.15港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452669.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","01477","BK1515","01672","BK1161","BK1191"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ocumension.com","stockEarnings":[{"period":"1week","weight":-0.0232},{"period":"1month","weight":-0.2564},{"period":"3month","weight":-0.3333},{"period":"6month","weight":-0.4082},{"period":"1year","weight":-0.5774},{"period":"ytd","weight":-0.373}],"compareEarnings":[{"period":"1week","weight":-0.037},{"period":"1month","weight":-0.0857},{"period":"3month","weight":-0.0581},{"period":"6month","weight":-0.0932},{"period":"1year","weight":-0.0316},{"period":"ytd","weight":-0.0866}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"欧康维视生物是一家主要从事眼科药物的研发和商业化的公司。该公司产品主要包括OT-401“优施莹”氟轻松玻璃体内植入剂、OT-702“博优景”阿柏西普眼内注射溶液、OT-402“维速达尔”注射用维替泊芬、OT-204“欧沁”玻璃酸钠滴眼液及OT-305“贝特舒”盐酸倍他洛尔滴眼液等。该公司产品主要用于治疗葡萄膜炎、眼底疾病、屈光矫正、干眼症（DED）、青光眼及角结膜炎等各种眼前及眼后段疾病。该公司主要在中国国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.097698},{"month":2,"riseRate":0.5,"avgChangeRate":-0.037557},{"month":3,"riseRate":0.5,"avgChangeRate":0.044668},{"month":4,"riseRate":0.5,"avgChangeRate":0.015642},{"month":5,"riseRate":0.5,"avgChangeRate":0.087204},{"month":6,"riseRate":0.666667,"avgChangeRate":0.065904},{"month":7,"riseRate":0.4,"avgChangeRate":-0.027707},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.064893},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.082685},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.121217},{"month":11,"riseRate":0.333333,"avgChangeRate":0.004503},{"month":12,"riseRate":0.5,"avgChangeRate":0.058088}],"exchange":"SEHK","name":"欧康维视生物-B","nameEN":"OCUMENSION-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"欧康维视生物-B,01477,欧康维视生物-B股票,欧康维视生物-B股票老虎,欧康维视生物-B股票老虎国际,欧康维视生物-B行情,欧康维视生物-B股票行情,欧康维视生物-B股价,欧康维视生物-B股市,欧康维视生物-B股票价格,欧康维视生物-B股票交易,欧康维视生物-B股票购买,欧康维视生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}